Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMA401 for chemotherapy-induced peripheral neuropathy
ACTRN12611001092987Phase 2Completed
- Sponsor
- Spinifex Pharmaceuticals
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of olodanrigan in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Spinifex Pharmaceuticals. Primary endpoint: Reduction in spontaneous neuropathic pain. Started Sep 2012; status: completed.
02
Drugs
olodanrigan
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on ACTRN12611001092987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001092987.